• Product NameKIN1148
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityA novel small-molecule adjuvant that acts through the RIG-I pathway and IRF-3 transcription factor to stimulate inN/Ate immunity and protection following viral infection. The adjuvant will be developed for an FDA-approved avian inluenza virus vaccine as well as evaluation in flavivirus vaccine platforms, including West Nile virus, because of the small molecules broad immune-enhancing activity.
• Target NameOthers
• CAS No. 1428729-56-9
• Calculated MW 361.44
• Formulation C19H11N3OS2
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Others
  SMILES:O=C(NC1=NC2=CC=C3C(N=CS3)=C2S1)C4=CC5=C(C=C4)C=CC=C5
  Pathways:Others
  Receptor:Others
  Boling pt:
  Melting pt:
  Solubility:DMSO: 100 mg/mL
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Probst P., et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting